This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
3wbl
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | + | ==Crystal structure of CDK2 in complex with pyrazolopyrimidine inhibitor== | |
| - | + | <StructureSection load='3wbl' size='340' side='right' caption='[[3wbl]], [[Resolution|resolution]] 2.00Å' scene=''> | |
| - | + | == Structural highlights == | |
| + | <table><tr><td colspan='2'>[[3wbl]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3WBL OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3WBL FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=PDY:N~7~-(4-ETHOXYPHENYL)-6-METHYL-N~5~-[(3S)-PIPERIDIN-3-YL]PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE'>PDY</scene></td></tr> | ||
| + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3a2c|3a2c]]</td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CDK2, CDKN2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr> | ||
| + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Cyclin-dependent_kinase Cyclin-dependent kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.22 2.7.11.22] </span></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3wbl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3wbl OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3wbl RCSB], [http://www.ebi.ac.uk/pdbsum/3wbl PDBsum]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Mitogen-activated protein kinase-activated protein kinase 2 (MK2 or MAPKAP-K2) is a Ser/Thr kinase from the p38 mitogen-activated protein kinase signalling pathway and plays an important role in inflammatory diseases. The crystal structure of the MK2-TEI-I01800 complex has been reported; its Gly-rich loop was found to form an alpha-helix, not a beta-sheet as has been observed for other Ser/Thr kinases. TEI-I01800 is 177-fold selective against MK2 compared with CDK2; in order to understand the inhibitory mechanism of TEI-I01800, the cyclin-dependent kinase 2 (CDK2) complex structure with TEI-I01800 was determined at 2.0 A resolution. Interestingly, the Gly-rich loop of CDK2 formed a beta-sheet that was different from that of MK2. In MK2, TEI-I01800 changed the secondary structure of the Gly-rich loop from a beta-sheet to an alpha-helix by collision between Leu70 and a p-ethoxyphenyl group at the 7-position and bound to MK2. However, for CDK2, TEI-I01800 bound to CDK2 without this structural change and lost the interaction with the substituent at the 7-position. In summary, the results of this study suggest that the reason for the selectivity of TEI-I01800 is the favourable conformation of TEI-I01800 itself, making it suitable for binding to the alpha-form MK2. | ||
| - | + | Crystal structure of human cyclin-dependent kinase-2 complex with MK2 inhibitor TEI-I01800: insight into the selectivity.,Fujino A, Fukushima K, Kubota T, Kosugi T, Takimoto-Kamimura M J Synchrotron Radiat. 2013 Nov;20(Pt 6):905-9. doi: 10.1107/S0909049513020736., Epub 2013 Sep 26. PMID:24121337<ref>PMID:24121337</ref> | |
| - | + | ||
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | == | + | ==See Also== |
| - | + | *[[Cell division protein kinase 2|Cell division protein kinase 2]] | |
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Cyclin-dependent kinase]] | [[Category: Cyclin-dependent kinase]] | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
| - | [[Category: Fujino, A | + | [[Category: Fujino, A]] |
| - | [[Category: Fukushima, K | + | [[Category: Fukushima, K]] |
| - | [[Category: Kosugi, T | + | [[Category: Kosugi, T]] |
| - | [[Category: Kubota, T | + | [[Category: Kubota, T]] |
| - | [[Category: Takimoto-Kamimura, M | + | [[Category: Takimoto-Kamimura, M]] |
[[Category: Binding site]] | [[Category: Binding site]] | ||
[[Category: Cyclin-dependent kinase 2]] | [[Category: Cyclin-dependent kinase 2]] | ||
Revision as of 09:58, 21 December 2014
Crystal structure of CDK2 in complex with pyrazolopyrimidine inhibitor
| |||||||||||
Categories: Cyclin-dependent kinase | Homo sapiens | Fujino, A | Fukushima, K | Kosugi, T | Kubota, T | Takimoto-Kamimura, M | Binding site | Cyclin-dependent kinase 2 | Drug design | Map kinase kinase 2 | Mk2 | Protein kinase inhibitor | Pyrazole | Pyrimidine | Structure-activity relationship | Transferase-transferase inhibitor complex | Tumor
